User login
Key clinical point: The platelet-to-lymphocyte ratio (PLR) was not significantly different among men with benign disease, clinically insignificant prostate cancer, and clinically significant prostate cancer prior to biopsy.
Major finding: Pre-biopsy PLR did not predict prostate cancer status at the time of a biopsy was in multivariate analysis, although PLR was higher in subset of patients with serum PSA levels less than 10 ng/mL, with clinically significant cancer.
Study details: The data come from a cohort study of 1652 men with elevated PSA levels who underwent standard 12-core transrectal ultrasound-guided prostate biopsy (TRUS-Bx) to determine prostate cancer status.
Disclosures: The study was supported in part by the Korea Medical Device Development Fund. The researchers had no financial conflicts to disclose.
Source: Lee JW et al. Sci Rep. 2021 Jul 9. doi: 10.1038/s41598-021-93637-3.
Key clinical point: The platelet-to-lymphocyte ratio (PLR) was not significantly different among men with benign disease, clinically insignificant prostate cancer, and clinically significant prostate cancer prior to biopsy.
Major finding: Pre-biopsy PLR did not predict prostate cancer status at the time of a biopsy was in multivariate analysis, although PLR was higher in subset of patients with serum PSA levels less than 10 ng/mL, with clinically significant cancer.
Study details: The data come from a cohort study of 1652 men with elevated PSA levels who underwent standard 12-core transrectal ultrasound-guided prostate biopsy (TRUS-Bx) to determine prostate cancer status.
Disclosures: The study was supported in part by the Korea Medical Device Development Fund. The researchers had no financial conflicts to disclose.
Source: Lee JW et al. Sci Rep. 2021 Jul 9. doi: 10.1038/s41598-021-93637-3.
Key clinical point: The platelet-to-lymphocyte ratio (PLR) was not significantly different among men with benign disease, clinically insignificant prostate cancer, and clinically significant prostate cancer prior to biopsy.
Major finding: Pre-biopsy PLR did not predict prostate cancer status at the time of a biopsy was in multivariate analysis, although PLR was higher in subset of patients with serum PSA levels less than 10 ng/mL, with clinically significant cancer.
Study details: The data come from a cohort study of 1652 men with elevated PSA levels who underwent standard 12-core transrectal ultrasound-guided prostate biopsy (TRUS-Bx) to determine prostate cancer status.
Disclosures: The study was supported in part by the Korea Medical Device Development Fund. The researchers had no financial conflicts to disclose.
Source: Lee JW et al. Sci Rep. 2021 Jul 9. doi: 10.1038/s41598-021-93637-3.